Ascelia Pharma AB (ACE) Stock Overview

Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. It has two drug candidates in clinical development, which include Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, which is in Phase 2 trial for the treatment of gastric cancer. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.